Yunhan Tao, Huimin Yu, Yunxi Ma, Mingzhu Yuan, Guochong Chen, Jun Liu, Xi Chen, Xufang Sun
PDME is characterized by elevated BMI, serum triglyceride, low SRF incidence, but a higher rate of DRIL and vitreoretinal interface abnormality. Purine metabolism and DNA repair pathways were associated with treatment response and correlated with OCT structural changes. Metabolomic signatures, particularly the purine score, emerged as promising candidate markers associated with pDME in this exploratory cohort, warranting further validation in independent studies. A novel mechanism of pDME, the purine metabolism-DNA repair axis, was proposed and needs further verification.
PURPOSE: This exploratory study integrates aqueous humour metabolomic data with clinical and imaging features to examine candidate biomarkers and characterize multimodal patterns associated with persistent diabetic macular edema (pDME).
METHODS: In this prospective cohort study, DME patients were treated with monthly anti-VEGF injections over 3 months and categorized as pDME and non-pDME groups based on central subfield thickness and best-corrected visual acuity. We then carried out a nested case-control comparison of these groups, performing untargeted metabolomic analysis on aqueous humour samples. Comparison of clinical data, OCT parameters, and metabolites was performed. Logistic regression models were constructed to explore associations between multimodal features and pDME in the metabolomics subset.
RESULTS: A total of 103 patients (146 eyes) were finally included in the analysis. The pDME patients had significantly higher BMI (25.20 vs. 23.27, p = 0.004) and triglyceride (1.80 vs. 1.50, p = 0.003) levels when compared with non-pDME patients. A higher rate of disorganization of retinal inner layers (DRIL, p = 0.026) and vitreoretinal interface abnormality (p = 0.009), but a lower rate of SRF (p = 0.019), was found in the pDME group. Metabolomics analysis revealed 405 differentially expressed metabolites, and purine metabolism (p = 0.001, Q = 0.024) and DNA repair pathway (p < 0.001, Q = 0.013) were significantly enriched. Purine score and DNA repair score were both significantly higher in the pDME group compared with the non-pDME group (p < 0.001). ROC analysis demonstrated metabolomic markers, particularly the purine score, showed stronger group-wise separation for pDME than clinical and OCT features (LOOCV AUC 0.963 vs. 0.716 and 0.505). Additionally, vitreoretinal interface abnormality was associated with purine metabolism (OR = 5.820, 95% CI: 1.136-29.811) and DNA repair score (OR = 3.790, 95% CI: 1.096-13.109), while DRIL (OR = 0.214, 95% CI: 0.046-0.990) was associated with DNA repair score.
CONCLUSIONS: PDME is characterized by elevated BMI, serum triglyceride, low SRF incidence, but a higher rate of DRIL and vitreoretinal interface abnormality. Purine metabolism and DNA repair pathways were associated with treatment response and correlated with OCT structural changes. Metabolomic signatures, particularly the purine score, emerged as promising candidate markers associated with pDME in this exploratory cohort, warranting further validation in independent studies. A novel mechanism of pDME, the purine metabolism-DNA repair axis, was proposed and needs further verification.